SOURCE: DiamiR Biosciences Corp.

DiamiR Biosciences Corp.

September 26, 2016 08:02 ET

DiamiR Provides Update on Its Patent Portfolio, Launches New Website

MONMOUTH JUNCTION, NJ--(Marketwired - September 26, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, reported today that the following new patents have been issued or allowed between April and September 2016:

"Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases" in Europe (issued in the United States in February 2014);

"Methods of using miRNA from bodily fluids for early detection and monitoring of Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD)" in the United States, Japan, China, and Australia;

"miRNA-based Universal Screening Test" in Europe.

"These new patents further strengthen our intellectual property portfolio focused on early detection, differential diagnosis and monitoring of brain health and other conditions," said Dr. Kira Sheinerman, CEO of DiamiR. "DiamiR is currently developing its first diagnostic product, CogniMIR™, for early, including pre-symptomatic, detection of neurodegeneration associated with mild cognitive impairment and Alzheimer's disease. Our goal is to provide researchers and clinicians with an effective tool to facilitate enrollment of better-defined clinical trial participants and to enable primary screening of larger, at-risk groups. Please visit our newly launched website for more information about the company, our technology and ongoing programs."

About DiamiR

DiamiR, a wholly-owned subsidiary of DiamiR Biosciences Corp., is a privately held molecular diagnostics company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's and Parkinson's diseases, and other conditions. The proprietary technology is based on quantitative analysis of brain-enriched microRNA signatures in plasma and is being developed for screening, patient stratification as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic and clinical centers, disease foundations and life sciences companies. For more information, please visit the company's website at www.diamirbio.com.

Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.

Contact Information